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ABSTRACT
Despite the increasing use of peripheral blood progenitor cells (PBPC) instead of bone marrow (BM) for
allogeneic hematopoietic stem cell transplantation (allo HSCT) from human leukocyte antigen (HLA)-
matched unrelated donors in children, the relative benefits and risks of both stem cell sources in the pediatric
setting remain largely unknown. Recently, the only larger study comparing the value of the 2 stem cell sources
in a young patient group was confined to transplantation from HLA-identical sibling donors in older children
and adolescents with acute leukemia. Based on the paucity of data in pediatric HLA-matched unrelated donor
transplantation, we analyzed the outcome of 23 BM and 38 PBPC transplantations performed at our center.
Neutrophil and platelet engraftment were achieved significantly faster in PBPC compared to BM recipients (18
versus 22 days and 26 versus 33 days; P < .001 and P  .03) whereas the risk for grade II-IV acute
graft-versus-host disease (aGVHD) (62% versus 55%; P  .53) and chronic GVHD (cGVHD 65% versus 59%;
P  .54) was comparable. As overall survival (OS; PBPC versus BM: 47.5%  8.6% versus 51.8%  10.5%; P
 .88) and relapse-free survival (43.3%  8.3% versus 51.8%  10.5%; P  .60) are without detectable
difference, PBPC and BM appear both as a valid stem cell source for HLA-matched unrelated donor trans-
plantation in children with hematologic malignancies.
© 2007 American Society for Blood and Marrow Transplantation
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Peripheral blood progenitor cells (PBPC) are in-
reasingly used instead of bone marrow (BM) for un-
elated donor allogeneic hematopoietic stem cell
ransplantation (alloHSCT) in children with hemato-
ogic malignancies [1]. Initially, PBPCs have been
ntroduced as an alternate stem cell source for
lloHSCT hypothesizing that their increased hema-
opoietic progenitor and immune cell content will lead o
338o prompter engraftment and more efﬁcient graft-
ersus-leukemia responses with improved outcome
rom both reduced transplant-related mortality
TRM) and relapse rate [2,3]. Furthermore, the
teadily increasing preference of volunteer donors for
BPC donation has also contributed to the observed
hift in the use of stem cell sources. In contrast to
ubstantial literature on the use of PBPC in adult
ecipients of matched related allografts, comparisons
f BM versus PBPC in the unrelated donor setting are
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PBPC versus BM for Unrelated alloHSCT in Children 1339parse for adult patients and virtually nonexistent for
hildren [4]. The few available studies in adults have
ielded conﬂicting results with regard to relapse-free
nd overall survival after PBPC compared to BM
ransplantation from human leukocyte antigen
HLA)-matched unrelated donors [5-8]. However,
elative beneﬁts of PBPC versus BM transplantation
ay substantially differ in children because of a lesser
ropensity to graft-versus-host disease (GVHD) in
ounger transplant recipients and different disease ki-
etics in childhood leukemia.
Recently, the only other larger study comparing
he value of the 2 stem cell sources in a young patient
roup was conﬁned to transplantation from HLA-
dentical sibling donors in older children and adoles-
ents with acute leukemia [9]. Based on the paucity of
ata in pediatric HLA-matched unrelated donor
ransplantation, we analyzed the long-term outcome
f 61 transplants performed at our center between
992 and 2004. In this ﬁrst detailed comparison be-
ween PBPC and BM in unrelated donor transplanta-
ion in children with hematologic malignancies we
emonstrate that there is no detectable difference in
RM, relapse rate and, most importantly, long-term
elapse-free and OS in pediatric patients transplanted
ith either stem cell source.
ATIENTS, MATERIALS AND METHODS
atient, Disease, and Transplant Characteristics
All pediatric patients (18 years) with lymphohe-
atologic malignancies who were transplanted at our
enter with unmanipulated PBPC (n  38) or BM
n  23) from 5 of 6 HLA-matched unrelated do-
ors following myeloablative conditioning were in-
luded in this retrospective analysis. Table 1 provides
etails on the patient, disease, and transplant charac-
eristics of the study cohort regarding the parameters
f age, sex, and cytomegalovirus (CMV) serostatus of
oth recipient and donor as well as the patients’ dis-
ase and risk status, the stem cell source (PBPC versus
M) and year of transplantation, transplanted total
ucleated, and CD34 cell dose (the latter only for
BPC recipients), degree of donor-recipient matching
t the HLA-A, -B, and -DR1 locus, conditioning
egimen, and GVHD prophylaxis.
HLA-A and -B typing was performed either by se-
ologic (until 1998) or low-resolution molecular typing,
hereas HLA-DR1 typing was done by high-resolu-
ion molecular typing throughout the whole study pe-
iod [10]. Pretransplant conditioning with a total-body
rradiation (TBI-) versus busulfan-based regimen varied
ccording to patients’ age, disease, and risk status based
n the guidelines of the respective study protocols of the
Gesellschaft für Pädiatrische Onkologie und Häma-
ologie” (GPOH) and the “Pädiatrische Arbeitsgemein- schaft für Knochenmark- und Blutstammzelltransplan-
ation” (PA¨D-AG-KBT) and was myeloablative in all
ases. With regard to transplant indications patients with
cute lymphoblastic leukemia (ALL) and acute myelog-
nous leukemia (AML) in ﬁrst and second complete
emission, with chronic myelogenous leukemia (CML)
n ﬁrst chronic phase, non-Hodgkin lymphoma (NHL)
n remission and refractory cytopenia (RC) were consid-
red standard risk, whereas patients with ALL/AML in
qual to or greater than third complete remission or
onremission, CML equal to or greater than accelerated
hase, NHL in nonremission, myelodysplastic syn-
rome (MDS) with excess of blasts and juvenile my-
lomonocytic leukemia (JMML) were classiﬁed as
igh risk. Immunosuppressive therapy for prevention
f graft rejection and GVHD consisted of cyclosporin
(CSA)  methotrexate (MTX) combined with an-
ibody-/serotherapy in most cases (n  54) with a
inority of patients receiving MTX  CSA alone
n  3) or CSA  antibody-/serotherapy (n  4).
tudy Endpoints
As the endpoints of this retrospective analysis,
ematologic recovery, acute and chronic GVHD
aGVHD, cGVHD), relapse rate, TRM, death of dis-
ase (DOD), relapse-free survival (RFS) and OS were
ompared following PBPC versus BM transplantation.
eutrophil engraftment was deﬁned as achievement
f an absolute neutrophil count (ANC) 500/L
nd/or a white blood cell count 1000/L for 3
onsecutive days, platelet engraftment as achievement
f a platelet count 50,000/L for 3 consecutive days
ithout platelet support in the previous 7 days. For
nalysis of aGVHD and cGVHD only patients with
vidence of donor engraftment and survival beyond
ay 100 (for cGVHD) were considered evaluable.
VHD assessment was based on clinical signs and
ymptoms, laboratory tests, and biopsy, if applicable.
GVHD and cGVHD were graded according to pre-
iously described criteria [11,12]. TRM was deﬁned as
eath in remission, DOD as death following relapse of
he underlying hematologic malignancy. RFS was de-
ned as survival in complete remission; death and
elapse were considered events and surviving patients
ere censored at last follow-up. For analysis of OS,
eath was the event and surviving patients were cen-
ored at last follow-up.
tatistical Analysis
For statistical comparisons between the PBPC and
M groups the Fisher’s exact test was used for cate-
oric parameters and the Mann-Whitney test for con-
inuous variables. Kaplan-Meier estimates and the
og-rank test were employed for comparison of time-
ependent outcome parameters following PBPC ver-
us BM transplantation [13]. Multivariate analysis us-
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R. Meisel et al.1340able 1. Characteristics of the Study Cohorts
PBPC BM
Variable No. (%) No. (%) P
otal No. 38 23
atient age, years ns
Median 7.8 5.6
Range 0.6-18.0 0.8-18
atient sex, male 28 (74%) 11 (48%) .06
atient CMV serostatus ns
neg. 28 (74%) 17 (74%)
pos. 10 (26%) 5 (22%)
onor age, years ns
Median 38 41
Range 24-57 21-54
onor sex, male 27 (71%) 13 (57%) ns
onor CMV serostatus ns
neg. 23 (61%) 14 (61%)
pos. 15 (39%) 9 (39%)
isease characteristics ns
ALL 17 (45%) 10 (44%)
CR1/CR2 13 (34%) 7 (30%)
CR>3/NR 4 (11%) 3 (13%)
AML 10 (26%) 6 (26%)
CR1/CR2 6 (18%) 6 (26%)
CR>3/NR 4 (11%) 0 (0%)
MDS/JMML 7 (18%) 3 (13%)
RC 3 (8%) 0 (0%)
RAEB/RAEB-T 2 (5%) 2 (13%)
JMML 2 (5%) 1 (4%)
CML 2 (5%) 3 (13%)
CP1 2 (5%) 2 (9%)
CP>2 0 (0%) 1 (4%)
NHL 2 (5%) 1 (4%)
CR1 1 (3%) 0 (0%)
NR 1 (3%) 1 (4%)
isk status* ns
Standard 25 (66%) 16 (70%)
High 13 (34%) 7 (30%)
Nonremission (ALL  AML) 6 (16%) 1 (4%) .2
onditioning .01
TBI-based 22 (58%) 21 (91%)
Busulfan-based 16 (42%) 2 (9%)
VHD prophytaxis ns
MTX  CSA 3 (8%) 0
MTX  CSA  antibody† 31 (82%) 23 (100%)
CSA  antibody†  other 4 (10%) 0
ear of transplantation <.001
Median 2001 1995
Range 1997-2004 1992-2003
LA match (HLA-A,-B,-DR) ns
6/6 36 (95%) 19 (83%)
5/6 2 (5%) 4 (17%)
ucleated cell dose, 108/kg <.001
Median 15.5 7.0
Range 6.2-42.0 2.8-14.6
D34 cell dose 106/kg
Median 10.0 nd
Range 2.1-21.0 nd
BPC indicates peripheral blood progenitor cells; BM, bone marrow; No, number; ns, not signiﬁcant; CMV, cytomegalovirus; ALL, acute
lymphoblastic leukemia; CR, complete remission; NR, nonremission; AML, acute myeloblastic leukemia; MDS, myelodysplastic syndrome;
JMML, juvenile myelomonocytic leukemia; RC, refractory cytopenia; RAEB, refractory anemia with excess blasts; RAEB-T, refractory anemia
with excess blasts in transformation; CML, chronic myelogenous leukemia; CP, chronic phase; NHL, non-Hodgkin lymphoma; TBI, total-body
irradiation; GVHD, graft-versus-host disease; CSA, cyclosporine A; MTX, methotrexate; HLA, human leukocyte antigen; nd, not determined.
Standard risk: ALL/AML in ﬁrst and second complete remission, CML in ﬁrst chronic phase, MDS-refractory cytopenia, NHL in complete
remission; high risk: ALL/AML in equal to or greater than third complete remission or nonremission, CML equal to or greater than accelerated
phase, MDS-refractory anemia with excess of blasts, JMML, NHL in nonremission.Antibody was ATG/ALG during conditioning and/or anti-interleukin2-receptor antibody BT563/leukotac™ posttransplantation.
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PBPC versus BM for Unrelated alloHSCT in Children 1341ng Cox regression was carried out to determine the
mpact of potential risk factors on OS as the clinically
ost relevant outcome parameter [14]. Those patient,
isease, and transplant variables with a P-value .2 in
nivariate analysis were entered into the ﬁnal model
ith the exception of the parameter stem cell source,
hich was held in the model regardless of P-value. All
-values are 2 sided, with P  .05 considered statisti-
ally signiﬁcant. Statistical analyses were performed
sing the SPSS software package (Version 12.0.1).
ESULTS
tudy Cohort
Sixty-one patients were included into the study: 38
n the PBPC, and 23 in the BM transplant group.
atient and donor characteristics were comparable
etween the 2 groups with the exception of a statisti-
ally nonsigniﬁcant trend toward a higher proportion
f male patients (74% versus 48%; P  .06) in the
BPC compared to the BM group (Table 1). Like-
ise, disease categories were similarly distributed in
oth groups. However, 16% versus 4% of acute leu-
emia patients in the PBPC versus BM group did not
chieve remission prior to transplantation (P  .2),
nd therefore constitute a very high-risk group. With
egard to transplant characteristics, about half of the
atients in the PBPC group and the majority of pa-
ients in the BM group received TBI-based condition-
ng therapy (58% versus 91%, P .01). Because of the
ater establishment of PBPC as a stem cell source for
SCT, the time period during which transplantation
ith PBPC was performed is shorter than for BM
1997-2004 versus 1992-2003), and consequently, me-
ian year of transplant was more recent in the PBPC
roup (P  .001). Also as expected, PBPC allografts
ontained an approximately 2.2 times higher total nu-
leated cell dose than those from BM donors (P 
001).
ngraftment
Primary neutrophil engraftment was attained in
7 of 38 (97%) PBPC and 22 of 23 (96%) BM trans-
lant recipients despite the lack of prophylactic ad-
inistration of hematopoietic growth factors. Two
atients died without achieving neutrophil engraft-
ent on day 6 and day 31 after transplantation,
espectively, because of refractory progressive AML
nd sepsis with multiorgan failure. Time to myeloid
ngraftment was signiﬁcantly shorter after PBPC
ransplantation (median 18 days, range: 9-28 days)
ompared to BM transplantation (median 22 days,
ange 14-43 days, P  .001; Figure 1A). Similarly,
latelet recovery in patients transplanted with PBPC
median 26 days, range: 15-104 days) was achieved 7 oays earlier than in patients who received BM (median
3 days, range: 20-128 days, P  .03; Figure 1B).
GVHD and cGVHD
The cumulative incidence of clinically relevant
GVHD grade II-IV (PBPC versus BM: 62%  8%
ersus 55%  11%, P  .53; Figure 2A) and severe
GVHD grade III and IV (PBPC versus BM: 30% 
% versus 23%  9%, P  .52; Figure 2B) was
omparable between both groups. Also, the incidence
igure 1. Time to neutrophil and platelet engraftment. The cumu-
ative probability of reaching neutrophil (A) and platelet (B) engraft-
ent is shown for the PBPC group (dotted line) and BM group
solid line). N, number of patients evaluable in each arm of the study
ohort; Ev, number of events (neutrophil/platelet engraftment) ob-
erved in each arm.f cGvHD did not differ signiﬁcantly between PBPC
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R. Meisel et al.1342nd BM allograft recipients (65%  10% versus
9% 13%, P .54; Figure 3A). However, there was
statistically nonsigniﬁcant trend towards a higher
isk for clinically extended cGVHD with 50%  10%
ersus 26%  11% of patients in the PBPC versus
M groups, respectively (P .14; Figure 3B). Further
nalyses of the clinical impact of extended cGVHD on
ong-term outcome revealed that in 9 of 12 (75%)
urviving patients extended cGVHD resolved without
isabling sequelae, whereas 1 patient was lost to fol-
ow-up. Consequently, only 2 patients still exhibited
igure 2. Incidence of aGVHD. The cumulative incidences of
rade II-IV (A) and grade III-IV (B) aGVHD is shown for the
BPC group (dotted line) and BM group (solid line). N, number of
valuable patients in each arm of the study cohort; Ev, number of
vents (grade II-IV/III-IV aGVHD) observed in each arm.VHD-related functional impairment involving ei- aher the skin or lungs at last follow-up. With regard to
VHD-related mortality we could not detect any
ifference between the 2 stem cell sources: 7 patients,
of 23 (9%) from the BM and 5 of 38 (13%) from the
BPC group died from GVHD-related complications
P  .70).
RM, Relapse, and Survival
The trend toward a higher risk for extended
GVHD in the PBPC group (Figure 3B). did not
ranslate into any detectable difference in TRM: A
B
A
PBPC: 0.65 ± 0.10
BM: 0.59 ± 0.13
BM: N = 16, Ev = 9 (56%)
PBPC: N = 27, Ev = 11 (63%)
p = 0.54
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igure 3. Incidence of cGvHD. The cumulative incidences of any
rade (A) and clinically extensive (B) cGVHD is shown for the
BPC group (dotted line) and BM group (solid line). N, number of
valuable patients in each arm of the study cohort; Ev, number of
vents (any grade/clinically extensive cGvHD) observed in each
rm.
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PBPC versus BM for Unrelated alloHSCT in Children 1343otal of 17 patients, 11 (29%) from the PBPC and 6
26%) from the BM cohort, died of transplant-related
omplications between days 22 and 967 (median
24 days) after transplantation (P  .90). Likewise,
elapse of the underlying malignant disease occurred
n comparable frequency in both groups with 10 of 38
26%) patients from the PBPC group and 6 of 23
26%) patients from the BM group at a median of 88
ays after transplantation (P  1.0). With a median
ollow-up of 3.4 years (PBPC) and 10.0 years (BM)
FS and OS was without detectable difference be-
ween both groups (Figure 4). When nonremission
atients, whereas constitute an exceptional high risk
roup and were not evenly distributed between the
BPC and the BM group, were excluded from analy-
is, the survival curves became superimposable with
FS rates of 51.5%  9.2% versus 54.2%  10.7%
P  .97) and OS rates of 56.4%  9.5% versus
4.2%  10.7% (P  .73) for PBSC versus BM,
espectively. These clinically most relevant results
ere conﬁrmed in a multivariate analysis showing that
dvanced disease status at transplant (relative risk [RR]
.4, 95% conﬁdence interval [CI] 1.1-5.2, P  .02)
nd female donor sex (RR 2.2, 95% CI 1.04-4.70, P 
04) were signiﬁcant, independent risk factors for
ortality, whereas the stem cell source (PBPC versus
M) had no effect (RR 1.2, 95% CI 0.5-2.5, P  .69;
able 2). Moreover, those factors that were unevenly
istributed between the PBPC and BM groups, that is,
onditioning regimen, year of transplantation, and
ransplanted nucleated cell dose (Table 1), had no
igniﬁcant impact on relapse-free and OS in univariate
nd multivariate analysis (data not shown). Further
nalyses of the potential mechanism by which donor
ex affects OS revealed that children transplanted
rom a female donor carry a signiﬁcantly higher risk
or aGVHD grade III-IV (50% versus 15% in female
able 2. Multivariate Analysis of Risk Factors for Mortality
Variable*
Relative
Risk 95% CI P
tem cell source, PBPC 1.17 0.54-2.53 .69
isk status, high 2.40 1.12-5.15 .02
onor sex, female 2.21 1.04-4.70 .04
LA-match, 5/6 antigens 1.25 0.41-3.80 .69
I indicates conﬁdence interval; PBPC, peripheral blood progeni-
tor cells; HLA, human leukocyte antigen.
Variables analyzed for prognostic impact on mortality: age, sex,
and cytomegalovirus serostatus of both recipient and donor,
patients’ disease and risk status, stem cell source (PBPC versus
BM), year of transplantation, transplanted total nucleated cell
dose, degree of donor-recipient HLA matching, conditioning
regimen, and GVHD prophylaxis. Only variables with a P-value
.2 in univariate analysis were entered into the ﬁnal multivar-
iate model with the exception of the parameter stem cell source,
which was held in the model irrespective of P-value.ersus male donor transplantion; P  .01), and this sranslates into a higher rate of TRM (48% versus
8%; P  .03).
ISCUSSION
After more than a decade of experience in G-CSF-
obilized T cell replete PBPC transplantation, a
umber of clinical studies comparing PBPC with BM
or alloHSCT have consistently documented more
apid engraftment but have yielded conﬂicting results
ith regard to other critical outcome parameters
4-8]. Particularly in pediatric transplantation, a de-
ailed comparison between the 2 stem cell sources in
igure 4. Probability of relapse-free survival (RFS) and overall survival
OS). RFS (A) and OS (B) is depicted for the PBPC group (dotted line)
nd BM group (solid line). N, number of patients in each arm of the
tudy cohort; Ev, number of events observed in each arm.
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R. Meisel et al.1344lloHSCT from unrelated donors is missing. Here we
resent the ﬁrst single center analysis of the outcome
ollowing PBPC versus BM transplantation for hema-
ologic malignancies from HLA-matched unrelated
onors in an entirely pediatric cohort.
In keeping with most adult studies, we observed a
igniﬁcantly shorter time to neutrophil and platelet
ngraftment after PBPC compared to BM transplan-
ation with a difference in median time to engraftment
f 4 and 7 days, respectively. As the use of MTX has
een associated with a delay in neutrophil engraftment
ollowing alloHSCT [15,16], it is of particular note
hat in our study 90% of patients in both the PBPC
nd the BM group received an MTX-containing
VHD prophylaxis regimen such that a potential bias
rom differential MTX usage can be excluded. Thus,
he swifter engraftment in the PBPC group is most
ikely attributable to the higher progenitor and stem
ell content in PBPC compared to BM grafts. This
bservation is in accordance with the results of virtu-
lly all studies in the HLA-identical sibling setting and
he few available studies in adult recipients of HLA-
atched unrelated donor alloHSCT [4-9,17]. How-
ver, as in the majority of these studies, in our analysis
aster engraftment in the PBPC group did not translate
nto any detectable reduction in TRM. This may be a
onsequence of the routine implementation of early
road spectrum antimicrobial therapy as the standard of
are for neutropenic fever after alloHSCT.
One of the major concerns when using PBPC
nstead of BM is the increased risk of clinically rele-
ant aGVHD and cGVHD related to the approxi-
ately 10-fold higher T cell content in PBPC grafts.
e found no difference in the incidences of aGVHD
rade II-IV (62% versus 55%, P  .53) and severe
GVHD grade III-IV (30% versus 23%, P  .52)
etween the PBPC and the BM group. Again, our
ata on comparable aGVHD in pediatric unrelated
lloHSCT using PBPC and BM reﬂect the results of
he IBMTR study in pediatric HLA-identical sibling
ransplantation [9] and a larger retrospective compar-
son of PBPC versus BM transplantation in HLA-
atched unrelated donor transplantation in adults [6].
ith regard to overall incidence of cGVHD, we
ould also not detect any signiﬁcant difference (PBPC
ersus BM: 65% versus 59%, P  .54). However, a
trong but statistically nonsigniﬁcant trend toward a
igher risk for clinically extended cGVHD (50% ver-
us 26%; P .14) was observed in the PBPC group. A
igher propensity to cGVHD in recipients of PBPC
rafts has been observed in the majority of random-
zed studies in related alloHSCT comparing PBPC
ith BM for adults and the above-mentioned retro-
pective IBMTR study of HLA-identical sibling trans-
lantation in older children and adolescents [4,9].
ikewise, a recent follow-up report to the above men-
ioned retrospective study on the long-term outcome Pollowing PBPC versus BM transplantation in the
dult matched unrelated donor setting found a higher
ncidence of extensive cGVHD in the PBPC group
18]. To assess the potential clinical impact of a higher
ate of extensive cGVHD in pediatric unrelated donor
ransplantation we compared the proportion of GVHD-
elated deaths in the PBPC and the BM group in our
ohort and found the overall incidence to be low and
ithout difference between the PBPC and BM group
13% versus 9%, P  .7). Moreover, we found that
verall 9 of 12 patients suffering from clinically exten-
ive cGVHD subsequently recovered without dis-
bling sequelae, whereas only 2 patients still exhibited
VHD-related functional impairment at last follow-
p. Thus, the trend toward an increased risk for ex-
ended cGVHD following PBPC from matched-
nrelated donors in children does not result in a
igher rate of TRM. Although quality of life may be
ffected in long-term survivors with cGVHD, this
ssue still needs to be adequately addressed in future
tudies of larger patient cohorts.
As the clinically most relevant outcome parame-
ers for children with hematologic malignancies we
nalyzed RFS and OS in recipients of PBPC and BM
ransplantation. As a consequence of comparable rates
f relapses and TRM in both groups, we found no
igniﬁcant difference in RFS (43.3% versus 51.8%;
 .60) and OS (47.5% versus 51.8%; P  .88)
etween PBPC and BM recipients. This result was
eriﬁed in a multivariate analysis of OS including
hose risk factors as covariates that were unevenly
istributed between the PBPC and the BM groups,
hus conﬁrming that the stem cell source has no sig-
iﬁcant impact on overall outcome in unrelated pedi-
tric alloHSCT. This result is in contrast to the IB-
TR study on HLA-identical sibling transplantation
n older children with acute leukemia, which revealed
10% higher mortality rate in the PBPC group [9].
hus, our observation underscores the notion that the
elative beneﬁts of PBPC versus BM as a stem cell
ource may well depend on the disease entities treated,
he donor type (ie, related versus unrelated) as well as
he patient age. However, as our study was retrospec-
ive and involved a limited number of patients, it may
urrently not be sufﬁciently powered to detect a
maller difference in outcome between recipients of
M and PBPC transplants. Therefore, to further de-
ne the role of PBPC versus BM for alloHSCT from
LA-matched unrelated donors in children with he-
atologic malignancies, prospective studies compris-
ng a higher number of patients are clearly warranted.
n this regard, a prospective randomized trial cur-
ently performed by the Blood and Marrow Trans-
lant Clinical Trials Network (BMT CTN) in the
nited States adresses this issue by comparing gran-
locyte-colony stimulating factor (G-CSF) mobilized
BPC with marrow transplantation from HLA com-
p
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PBPC versus BM for Unrelated alloHSCT in Children 1345atible unrelated donors. However, the results of this
rial, which also includes pediatric patients, will only
e available in a couple of years, as recruitment is still
ngoing. In the meantime, however, it remains im-
ortant to note that there are currently no pediatric
ata justifying the preferential use of either PBPC or
M as stem cell source for unrelated alloHSCT. We
elieve that this fact may also be of relevance when
ounseling unrelated volunteer donors.
CKNOWLEDGMENTS
We thank Arndt Borkhardt (Clinic for Pediatric
ncology, Hematology and Clinical Immunology,
niversity Clinic of Düsseldorf, Heinrich-Heine-
niversity, Düsseldorf, Germany) for critical reading
f the manuscript and the nursing staff of the pediatric
MT unit of University Clinic Düsseldorf for excellent
atient care. The stem cell transplantation programme
f the University Clinic Düsseldorf is generously sup-
orted by the Elterninitiative Kinderkrebsklink Düssel-
orf e.V. All authors declare no conﬂicts.
EFERENCES
1. Miano M, Labopin M, Hartmann O, et al. Haematopoietic
stem cell transplantation trends in children over the last three
decades: a survey by the pediatric diseases working party of the
European Group for Blood and Marrow Transplantation. Bone
Marrow Transplant. 2007;39:89-99.
2. Bensinger WI, Clift R, Martin P, et al. Allogeneic peripheral
blood progenitor cell transplantation in patients with advanced
hematologic malignancies: a retrospective comparison with
marrow transplantation. Blood. 1996;88:2794-2800.
3. Ottinger HD, Beelen DW, Scheulen B, Schaefer UW and
Grosse-Wilde H. Improved immune reconstitution after allo-
transplantation of peripheral blood progenitor cells instead of
bone marrow. Blood. 1996;88:2775-2779.
4. Allogeneic peripheral blood stem-cell compared with bone
marrow transplantation in the management of hematologic
malignancies: an individual patient data meta-analysis of nine
randomized trials. J Clin Oncol. 2005;23:5074-5087.
5. Ringden O, Remberger M, Runde V, et al. Peripheral blood
progenitor cell transplantation from unrelated donors: a com-
parison with marrow transplantation. Blood. 1999;94:455-464.
6. Remberger M, Ringden O, Blau IW, et al. No difference in
graft-versus-host disease, relapse, and survival comparing pe-
ripheral stem cells to bone marrow using unrelated donors.
Blood. 2001;98:1739-1745.7. Elmaagacli AH, Basoglu S, Peceny R, et al. Improved disease-
free-survival after transplantation of peripheral blood progeni-
tor cells as compared with bone marrow from HLA-identical
unrelated donors in patients with ﬁrst chronic phase chronic
myeloid leukemia. Blood. 2002;99:1130-1135.
8. Garderet L, Labopin M, Gorin NC, et al. Patients with acute
lymphoblastic leukemia allografted with a matched unrelated
donor may have a lower survival with a peripheral blood pro-
genitor cell graft compared to bone marrow. Bone Marrow
Transplant. 2003;31:23-29.
9. Eapen M, Horowitz MM, Klein JP, et al. Higher mortality after
allogeneic peripheral-blood transplantation compared with
bone marrow in children and adolescents: the Histocompatibil-
ity and Alternate Stem Cell Source Working Committee of the
International Bone Marrow Transplant Registry. J Clin Oncol.
2004;22:4872-4880.
0. Knipper AJ, Hinney A, Schuch B, Enczmann J, Uhrberg M,
Wernet P. Selection of unrelated bone marrow donors by
PCR-SSP typing and subsequent nonradioactive sequence-
based typing for HLA DRB1/3/4/5, DQB1, and DPB1 alleles.
Tissue Antigens. 1994;44:275-284.
1. Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations
of graft-versus-host disease in human recipients of marrow
from HL-A-matched sibling donors. Transplantation. 1974;18:
295-304.
2. Shulman HM, Sullivan KM, Weiden PL, et al. Chronic graft-
versus-host syndrome in man. A long-term clinicopathologic
study of 20 Seattle patients. Am J Med. 1980;69:204-217.
3. Kaplan EL, Meier P. Nonparametric estimation from incom-
plete observations. J Am Stat Assoc. 1958;53:457-481.
4. Cox DR. Regression models and life tables. J R Stat Soc. 1972;
34:187-220.
5. Deeg HJ, Storb R, Thomas ED, et al. Cyclosporine as prophy-
laxis for graft-versus-host disease: a randomized study in pa-
tients undergoing marrow transplantation for acute nonlym-
phoblastic leukemia. Blood. 1985;65:1325-1334.
6. Locatelli F, Bruno B, Zecca M, et al. Cyclosporin A and short-
term methotrexate versus cyclosporin A as graft versus host
disease prophylaxis in patients with severe aplastic anemia given
allogeneic bone marrow transplantation from an HLA-identical
sibling: results of a GITMO/EBMT randomized trial. Blood.
2000;96:1690-1697.
7. Meisel R, Enczmann J, Balzer S, et al. Similar survival following
HLA-identical sibling transplantation for standard indication in
children with haematologic malignancies: a single center com-
parison of mobilized peripheral blood progenitor cell with bone
marrow transplantation. Klin Padiatr. 2005;217:135-141.
8. Remberger M, Beelen DW, Fauser A, Basara N, Basu O, Ringden
O. Increased risk of extensive chronic graft-versus-host disease
after allogeneic peripheral blood progenitor cell transplantation
using unrelated donors. Blood. 2005;105:548-551.
